<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Paraneoplastic syndromes affecting spinal cord, peripheral nerve, and muscle</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Paraneoplastic syndromes affecting spinal cord, peripheral nerve, and muscle</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Paraneoplastic syndromes affecting spinal cord, peripheral nerve, and muscle</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Josep Dalmau, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Myrna R Rosenfeld, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Y Wen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 18, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Paraneoplastic neurologic syndromes are a heterogeneous group of neurologic disorders associated with systemic cancer and caused by mechanisms other than metastases, metabolic and nutritional deficits, infections, coagulopathy, or side effects of cancer treatment. These syndromes may affect any part of the nervous system from cerebral cortex to neuromuscular junction and muscle, damaging either one area or multiple areas. They can occur with or without detectable autoantibodies in serum and cerebrospinal fluid (CSF).</p><p>Paraneoplastic syndromes affecting the spinal cord, dorsal root ganglia, peripheral nerve, neuromuscular junction, and muscle will be reviewed here. An overview of the diagnosis of neurologic paraneoplastic syndromes and the clinical features and treatment of paraneoplastic disorders affecting other parts of the central nervous system (CNS) are reviewed separately. (See  <a class="medical medical_review" href="/d/html/5188.html" rel="external">"Overview of paraneoplastic syndromes of the nervous system"</a> and  <a class="medical medical_review" href="/d/html/15759.html" rel="external">"Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/15822.html" rel="external">"Paraneoplastic cerebellar degeneration"</a> and  <a class="medical medical_review" href="/d/html/15837.html" rel="external">"Paraneoplastic visual syndromes"</a>.)</p><p class="headingAnchor" id="H3227858855"><span class="h1">SPINAL CORD SYNDROMES</span></p><p class="headingAnchor" id="H3765636281"><span class="h2">Myelopathy</span><span class="headingEndMark"> — </span>Paraneoplastic myelopathy, resulting in rapidly progressive spastic paresis with or without bowel and bladder dysfunction, usually occurs in association with involvement of other areas of the nervous system; examples include encephalitis, sensory neuronopathy, chorea, and optic neuropathy [<a href="#rid1">1-3</a>]. The most commonly associated antibodies are anti-Hu, anti-collapsin-responsive mediator protein 5 (CRMP5), and, less frequently, antiamphiphysin antibodies  (<a class="graphic graphic_table graphicRef135170" href="/d/graphic/135170.html" rel="external">table 1</a>). The usual culprit is small cell lung cancer (SCLC).</p><p>Paraneoplastic myelopathy can also occur as an isolated syndrome. In such cases, the differential diagnosis is broad and includes a variety of other causes of spinal cord dysfunction and signal abnormality on spine magnetic resonance imaging (MRI). (See  <a class="medical medical_review" href="/d/html/5093.html" rel="external">"Disorders affecting the spinal cord"</a>.)</p><p>In a case series of 31 patients with an isolated progressive paraneoplastic myelopathy, the most common coexisting cancers were lung and breast; kidney cancer, thyroid cancer, gynecologic cancers, and melanomas were also present in a few patients [<a href="#rid4">4</a>]. Antibodies to amphiphysin and CRMP5 were the most commonly identified paraneoplastic biomarkers, observed in eight and nine patients, respectively. Patients presented with subacute or insidiously progressive myelopathy symptoms, usually symmetric, leading to wheelchair dependence in half of patients. Spine MRI abnormalities, identified in 20 patients, included longitudinally extensive T2-hyperintense signal abnormality (extending over more than three vertebral segments), often associated with contrast enhancement. Cerebrospinal fluid (CSF) analysis often showed elevated protein levels and/or pleocytosis. Most patients did not improve, even after oncologic and/or immunosuppressive therapy. The study suggests that in patients with new-onset progressive myelopathy of unknown cause, the presence of symmetric, longitudinally extensive tract or gray matter-specific changes on spinal MRI should raise suspicion for a paraneoplastic etiology.</p><p>There are reports of patients with neuromyelitis optica spectrum disorder (NMOSD) and aquaporin-4 (AQP4) antibodies who have or later develop cancer [<a href="#rid5">5,6</a>]. The most common cancer associations are lung and breast carcinomas, but other solid tumors and lymphoma have also been reported. The frequency of paraneoplastic NMOSD is rare, and routine screening of NMOSD patients for cancer is not indicated. Based on one study, however, the presence of brainstem involvement with severe nausea and vomiting, particularly in older males (&gt;45 years of age), may warrant cancer screening due to higher risk of a cancer association [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/14089.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Clinical features and diagnosis"</a>.)</p><p>There are rare reports of a paraneoplastic necrotizing myelopathy. In one report of a patient with paraneoplastic necrotizing myelopathy who responded to treatment with corticosteroids but eventually died of complications of metastatic esophageal cancer, the autopsy confirmed the presence of necrosis of the spinal cord and mild inflammatory infiltrates [<a href="#rid7">7</a>].</p><p>The differential diagnosis of necrotizing myelopathy includes leptomeningeal, epidural, and intramedullary metastasis. In addition, necrotizing myelopathy can also result from viral infections (particularly of the herpes group), septic infarcts, and toxic effects of intrathecal chemotherapy and radiation therapy [<a href="#rid8">8,9</a>]. It has also been suggested that some cases of necrotizing myelopathy are secondary to NMOSD. (See  <a class="medical medical_review" href="/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy"</a> and  <a class="medical medical_review" href="/d/html/5093.html" rel="external">"Disorders affecting the spinal cord"</a> and  <a class="medical medical_review" href="/d/html/14089.html" rel="external">"Neuromyelitis optica spectrum disorder (NMOSD): Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H174936380"><span class="h2">Subacute motor neuronopathy</span><span class="headingEndMark"> — </span>Paraneoplastic degeneration of the anterior horn cells, referred to as subacute motor neuronopathy, was initially reported in patients with Hodgkin and non-Hodgkin lymphoma [<a href="#rid10">10-13</a>]. The disorder is characterized by subacute, progressive, painless, and often asymmetric lower motor neuron weakness. Although some patients have sensory symptoms, the neurologic examination reveals few or no objective sensory deficits.</p><p>Pathologic findings include severe neuronal degeneration of the anterior horn cells with variable inflammatory infiltrates, and demyelination with mild axonal loss of the posterior columns of the spinal cord [<a href="#rid10">10,11</a>].</p><p>The decreasing frequency of this syndrome over time suggests that the etiology could be a viral infection that was missed in the original descriptions. Alternatively, the disorder could be due to other causes that are currently prevented with the management of patients with lymphoma.</p><p>The course of the neurologic disorder is usually independent of the course of the lymphoma, although spontaneous neurologic improvement has been reported as well as improvement or stabilization in association with lymphoma treatment [<a href="#rid10">10,12,14</a>].</p><p class="headingAnchor" id="H438115436"><span class="h2">Stiff-person syndrome</span><span class="headingEndMark"> — </span>Stiff-person syndrome is an uncommon disorder characterized by progressive muscle stiffness, rigidity, and spasms predominantly involving the axial muscles of the trunk and proximal muscles of the limbs [<a href="#rid15">15,16</a>]. Muscle spasms are usually heightened by touch, noise, or emotional distress. In some patients, pruritus is the initial symptom of paraneoplastic stiff-person syndrome [<a href="#rid17">17</a>]. Related disorders include progressive encephalomyelitis with rigidity and myoclonus (PERM), in which patients develop symptoms similar to stiff-person syndrome along with brainstem dysfunction, seizures, or encephalopathy, and stiff-limb syndrome, in which one or more limbs are affected with distal rigidity. </p><p>Paraneoplastic stiff-person syndrome usually occurs in patients with breast cancer or SCLC [<a href="#rid15">15,16,18-20</a>]. The serum of these patients often contains antibodies against amphiphysin [<a href="#rid18">18,20,21</a>]. By contrast, patients with stiff-person syndrome who do not have cancer (but who usually develop diabetes and other symptoms of endocrinopathy) have antibodies against glutamic acid decarboxylase (GAD) [<a href="#rid22">22</a>]. Both GAD65 and amphiphysin are cytoplasmic proteins that are not exposed on the cell surface; it has been suggested that amphiphysin may be transiently exposed during the process of synaptic vesicle uptake and thereby accessed by circulating antibodies. (See  <a class="medical medical_review" href="/d/html/5131.html" rel="external">"Stiff-person syndrome", section on 'Pathogenesis'</a>.)</p><p>Antibodies to the alpha-1 subunit of the glycine receptor (GlyR)  (<a class="graphic graphic_table graphicRef135170" href="/d/graphic/135170.html" rel="external">table 1</a>) with or without concurrent GAD autoimmunity have been reported in some patients with stiff-person syndrome [<a href="#rid23">23</a>] but are more characteristic of PERM. Most patients with GlyR antibodies do not have cancer; however, in a study of 52 patients with PERM and GlyR antibodies, five patients had a previous history of neoplasms and four had tumors identified during the study of PERM (most common were breast cancer, thymoma, and lymphoma) [<a href="#rid24">24</a>]. A higher index of suspicion for cancer should be present in older adults and those who develop additional signs or symptoms such as limbic encephalitis, encephalomyelitis, or opsoclonus-myoclonus. </p><p>Treatment of paraneoplastic stiff-person syndrome consists of control of the tumor and the administration of symptomatic treatment of spasms and rigidity (eg, benzodiazepines, <a class="drug drug_general" data-topicid="9062" href="/d/drug information/9062.html" rel="external">baclofen</a>, <a class="drug drug_general" data-topicid="9999" href="/d/drug information/9999.html" rel="external">tizanidine</a>). In those who do not respond, glucocorticoids, intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG), or other immunosuppressive agents can be tried. Patients with GlyR antibodies appear to be more responsive than those without antibodies or with antibodies to GAD or amphiphysin [<a href="#rid25">25</a>].</p><p>The clinical features, diagnosis, and treatment of stiff-person syndrome are reviewed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/5131.html" rel="external">"Stiff-person syndrome"</a>.)</p><p class="headingAnchor" id="H2431080684"><span class="h1">DORSAL ROOT GANGLIA</span></p><p class="headingAnchor" id="H3905699484"><span class="h2">Subacute sensory neuronopathy</span><span class="headingEndMark"> — </span>Selective involvement of the dorsal root ganglia, referred to as sensory neuronopathy, results in a particularly disabling form of sensory loss with prominent sensory ataxia.</p><p>The sensory deficits of paraneoplastic subacute sensory neuronopathy typically begin with loss of vibratory sensation and joint position sense, followed by impairment in pain and temperature sensation [<a href="#rid26">26</a>]. Patients initially complain of pain or the sensation of "pins and needles" or "electric shocks." The symptoms may initially affect one extremity, but in a few weeks or months, they usually progress to involve other extremities, the face, the abdomen, or the trunk [<a href="#rid26">26,27</a>]. In a subset of patients, hyperalgesia and spontaneous pain remain the prominent symptoms, and sensory ataxia is mild or even absent [<a href="#rid28">28</a>].</p><p>On neurologic examination, there is usually moderate to severe involvement of all sensory modalities. These sensory deficits frequently lead to prominent ataxia, which is exacerbated by eye closure and associated with pseudoathetoid movements of the fingers and extremities. Other neurologic findings may include sensorineural hearing loss, diminished taste sensation, and symmetric or asymmetric reduction or loss of deep tendon reflexes.</p><p>As in other paraneoplastic disorders, symptoms typically predate the discovery of a tumor. The association with pain may erroneously lead to the diagnosis of radiculopathy or polyneuropathy. In one case control study, clinical features that distinguished this syndrome from a sensory neuropathy included limb ataxia, asymmetric distribution, and sensory loss other than in the legs [<a href="#rid29">29</a>].</p><p>Neurophysiologic studies usually show reduced or absent sensory potentials with normal or borderline motor nerve conduction velocities. Abnormal motor conduction velocity with axonal and demyelinating features may occur, complicating the differential diagnosis between peripheral nerve and dorsal root ganglia involvement. Neurophysiologic features that can help distinguish sensory neuronopathy from peripheral nerve disorder include at least one absent or three low (&lt;30 percent of normal) sensory action potentials in the arms with fewer than two abnormal motor nerve conduction studies (NCS) in the legs [<a href="#rid29">29</a>].</p><p>The cerebrospinal fluid (CSF) may be normal but often shows moderate pleocytosis, increased protein, intrathecal synthesis of immunoglobulin G (IgG), and oligoclonal bands.</p><p>Histologic examination reveals a mononuclear cell infiltrate in the dorsal root ganglia that is probably immune mediated, neuronal degeneration, and proliferation of the satellite cells (Nageotte nodules)  (<a class="graphic graphic_picture graphicRef65517" href="/d/graphic/65517.html" rel="external">picture 1</a>). There is also a variable involvement of the dorsal and ventral nerve roots, and secondary demyelination of the spinal cord dorsal columns [<a href="#rid27">27</a>]. Sural nerve biopsy shows a reduction in myelinated fiber density with depletion of large fibers most prominent in those with more severe sensory ataxia [<a href="#rid28">28</a>].</p><p>Approximately 80 percent of patients with paraneoplastic subacute sensory neuronopathy have small cell lung cancer (SCLC), usually in association with anti-Hu antibodies  (<a class="graphic graphic_table graphicRef135170" href="/d/graphic/135170.html" rel="external">table 1</a>). Many of these patients progress to paraneoplastic encephalomyelitis [<a href="#rid1">1</a>]. Some patients have anti-collapsin-responsive mediator protein 5 (CRMP5) antibodies, directed against antigens present on peripheral nerves, often in conjunction with anti-Hu antibodies [<a href="#rid30">30</a>]. If both antibodies are present, a mixed axonal and demyelinating sensory motor neuropathy may be superimposed on subacute sensory neuronopathy. Well-characterized paraneoplastic antibodies such as anti-Hu and anti-CRMP5 are almost always detectable in serum; only in rare instances will the CSF reveal antibodies undetected in serum. (See  <a class="medical medical_review" href="/d/html/5188.html" rel="external">"Overview of paraneoplastic syndromes of the nervous system", section on 'Diagnostic evaluation'</a>.)</p><p>Aside from SCLC, other tumors associated with subacute sensory neuronopathy include breast, prostate, or colon cancers; lymphoma; or uterine sarcoma. Thus, tumor screening with computed tomography (CT) and/or 18-F fluorodeoxyglucose positron emission tomography (FDG-PET) should be performed in patients with suspected paraneoplastic sensory neuronopathy [<a href="#rid31">31</a>].</p><p>The differential diagnosis also includes toxic side effects of chemotherapeutic drugs (such as <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>, and vinca alkaloids) and immune checkpoint inhibitors. Cisplatin neuropathy and paraneoplastic sensory neuronopathy can usually be distinguished by the fact that cisplatin produces a large fiber neuropathy affecting position and vibration sense almost exclusively and sparing pain and temperature sense, whereas the paraneoplastic disorder affects all sensory modalities. Sensory neuronopathy can also be seen in association with autoimmune disorders (eg, Sjögren's disease, celiac disease, autoimmune hepatitis) and infections (eg, Epstein-Barr virus, human immunodeficiency virus, varicella-zoster) [<a href="#rid32">32,33</a>]. (See  <a class="medical medical_review" href="/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy"</a> and  <a class="medical medical_review" href="/d/html/2826.html" rel="external">"Overview of neurologic complications of platinum-based chemotherapy"</a> and  <a class="medical medical_review" href="/d/html/5096.html" rel="external">"Approach to the patient with sensory loss", section on 'Sensory neuronopathies'</a>.)</p><p>Treatment with glucocorticoids, plasma exchange, and intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) is usually ineffective [<a href="#rid1">1,34,35</a>], although there are a few reported exceptions to this general rule [<a href="#rid36">36,37</a>]. In one report, the combination of IVIG plus <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> and <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> resulted in disease stabilization in 2 of 10 patients with anti-Hu antibody-associated paraneoplastic sensory neuronopathy [<a href="#rid36">36</a>]. Early diagnosis and treatment of the tumor is likely the best approach to stabilize (or improve) the neurologic symptoms.</p><p class="headingAnchor" id="H3035139609"><span class="h1">PERIPHERAL NERVE</span></p><p class="headingAnchor" id="H3079926506"><span class="h2">Acute sensorimotor radiculoneuropathy</span><span class="headingEndMark"> — </span>A disorder clinically identical to Guillain-Barré syndrome (GBS), acute sensorimotor radiculoneuropathy occurs at higher-than-expected frequency in patients with cancer, mostly Hodgkin and non-Hodgkin lymphomas and, less commonly, solid tumors [<a href="#rid38">38</a>]. Patients develop acute-onset rapidly progressive sensorimotor or pure motor neuropathy and the cerebrospinal fluid (CSF) shows elevated protein and normal or only slightly elevated cell counts. The neuropathy may develop at any stage of the cancer and can herald cancer recurrence. Treatment is the same as for GBS, with some studies suggesting that patients with cancer have worse neurologic outcomes [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/d/html/5172.html" rel="external">"Guillain-Barré syndrome in adults: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H214550449"><span class="h2">Chronic sensorimotor neuropathy</span><span class="headingEndMark"> — </span>A chronic sensorimotor neuropathy not due to an identifiable cause (eg, metabolic or nutritional deficits, chemotherapy toxicity, among others) may occur in cancer patients, mostly in patients with lung cancer and lymphoma. Symptoms typically develop in patients with advanced disease, well after the diagnosis of malignancy has been made. </p><p>Patients are usually not very debilitated by their neurologic symptoms, which typically consist of mild to moderate distal symmetric sensorimotor deficits. This type of neuropathy rarely associates with paraneoplastic antibodies and is slowly progressive, with weakness a late occurrence.</p><p>By contrast, patients with paraneoplastic antibodies (eg, collapsin-responsive mediator protein 5 [CRMP5]) develop a more rapidly progressive sensorimotor neuropathy; these antibodies usually associate with small cell lung cancer (SCLC) or thymoma. Electrophysiologic studies show a mix of axonal and demyelinating features [<a href="#rid30">30</a>]. These neuropathies are very disabling and respond poorly to immunotherapy or treatment of the tumor.</p><p class="headingAnchor" id="H262656293"><span class="h2">Neuropathies associated with lymphoproliferative disorders</span><span class="headingEndMark"> — </span>Peripheral neuropathy can be a manifestation of several lymphoproliferative disorders associated with elevated paraprotein, including multiple myeloma, POEMS (<strong>P</strong>olyneuropathy, <strong>O</strong>rganomegaly, <strong>E</strong>ndocrinopathy, <strong>M</strong>-protein, and <strong>S</strong>kin changes) syndrome, and Waldenström macroglobulinemia. These peripheral nerve syndromes are reviewed separately:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multiple myeloma</strong> – Peripheral neuropathy is uncommon in multiple myeloma at the time of initial diagnosis and, when present, is usually due to associated immunoglobulin light chain (AL) amyloidosis or POEMS. (See  <a class="medical medical_review" href="/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Neurologic disease'</a> and  <a class="medical medical_review" href="/d/html/6668.html" rel="external">"Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis", section on 'Systemic presentations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>POEMS syndrome</strong> – POEMS is a monoclonal plasma cell disorder in which neuropathy is a defining feature. In most cases, the neuropathy of POEMS is a symmetric, ascending sensorimotor polyneuropathy. Electrophysiologic and pathologic studies show both demyelination and axonal degeneration. The neuropathy is often the presenting feature of POEMS and may initially be confused with chronic inflammatory demyelinating polyneuropathy (CIDP). (See  <a class="medical medical_review" href="/d/html/6662.html" rel="external">"POEMS syndrome", section on 'Peripheral neuropathy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multicentric Castleman disease</strong> – Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder that may occur with or without POEMS syndrome. Neuropathy in patients with iMCD is variable and can range from a mild sensory neuropathy to the severe sensorimotor neuropathy of POEMS. (See  <a class="medical medical_review" href="/d/html/117312.html" rel="external">"HHV-8-negative/idiopathic multicentric Castleman disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Waldenström macroglobulinemia</strong> – Neuropathy is present in approximately 20 percent of patients with Waldenström macroglobulinemia at the time of diagnosis. The neuropathy is usually a distal, symmetric, and slowly progressive sensorimotor neuropathy. Neuropathies may occur with or without antibodies against myelin-associated glycoprotein (MAG), GM1 ganglioside, or asialo-GM1 ganglioside. (See  <a class="medical medical_review" href="/d/html/6657.html" rel="external">"Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia", section on 'Neuropathy'</a>.)</p><p></p><p class="headingAnchor" id="H3653075623"><span class="h2">Autonomic neuropathy</span><span class="headingEndMark"> — </span>Paraneoplastic autonomic dysfunction frequently accompanies other paraneoplastic symptoms, including encephalomyelitis and sensory neuronopathy, but it can be the only manifestation of an underlying malignancy [<a href="#rid39">39</a>].</p><p>Autonomic dysfunction is associated with a variety of symptoms including, among others, orthostatic hypotension, dry mouth, erectile dysfunction, sphincter incontinence, gastroparesis, intestinal pseudo-obstruction, and cardiac arrhythmias that can lead to sudden death [<a href="#rid40">40</a>]. Paraneoplastic enteric neuropathy is a limited form in which patients have isolated gastrointestinal dysmotility (gastroparesis). Signs of sympathetic hyperactivity, such as excessive spontaneous sweating, may occur as a true paraneoplastic phenomenon or from local infiltration of sympathetic nerves by the tumor. (See  <a class="medical medical_review" href="/d/html/2640.html" rel="external">"Gastroparesis: Etiology, clinical manifestations, and diagnosis"</a>.) </p><p>The tumor most frequently involved is SCLC; these patients usually have anti-Hu antibodies and, less frequently, anti-CRMP5 antibodies. Other tumors include carcinoma of the pancreas, thyroid, and rectum; Hodgkin lymphoma; and carcinoid tumors of the lung [<a href="#rid39">39,41</a>]. Some of these patients have antibodies against ganglionic acetylcholine receptors (AChR), which can also occur in patients without cancer [<a href="#rid42">42,43</a>].</p><p>The treatment should focus on antitumor treatment; immune therapy is more effective in patients with ganglionic AChR antibodies [<a href="#rid44">44</a>] than in patients with classic paraneoplastic antibodies (anti-Hu) or no antibodies.</p><p class="headingAnchor" id="H544417998"><span class="h2">Vasculitic neuropathy</span><span class="headingEndMark"> — </span>A paraneoplastic peripheral nerve vasculitis typically presents with painful, symmetric or asymmetric sensorimotor deficits resembling a multifocal mononeuropathy and, in some patients, proximal motor weakness [<a href="#rid45">45,46</a>]. The diagnosis is confirmed by biopsy, which shows a predominantly cytotoxic (CD8+) T cell infiltrate in small-sized vessels in the absence of necrosis and malignant cells [<a href="#rid47">47,48</a>]. (See  <a class="medical medical_review" href="/d/html/8236.html" rel="external">"Clinical manifestations and diagnosis of vasculitic neuropathies", section on 'Clinical Features'</a>.)</p><p>Diagnosis of the vasculitis usually precedes the discovery of a cancer. The tumors most frequently involved are cancer of the lung (usually SCLC), prostate, and endometrium, and both Hodgkin and non-Hodgkin lymphomas [<a href="#rid46">46</a>].</p><p>As with vasculitic neuropathies that are not associated with cancer, immunosuppressive therapy (eg, glucocorticoids, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>) is indicated and may lead to improvement in symptoms. Treatment of the tumor may also improve the neurologic disorder. (See  <a class="medical medical_review" href="/d/html/8221.html" rel="external">"Treatment and prognosis of nonsystemic vasculitic neuropathy"</a>.)</p><p class="headingAnchor" id="H4056179008"><span class="h2">Checkpoint inhibitor-associated neuropathies</span><span class="headingEndMark"> — </span>Immune checkpoint inhibitors used for cancer therapy have been associated with a variety of neurologic immune-related adverse events, including a wide range of neuropathy phenotypes [<a href="#rid49">49</a>]. Syndromes can occur in the presence or absence of autoantibodies to intracellular (onconeuronal) antigens [<a href="#rid50">50</a>]. Immune-related neuropathies are important to recognize and distinguish from other causes of neuropathy, as treatment may require withdrawal of the offending agent and glucocorticoids  (<a class="graphic graphic_table graphicRef116846" href="/d/graphic/116846.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'General principles'</a>.)</p><p>Accumulating reports describe a wide range of cranial and peripheral neuropathies associated with checkpoint inhibitor therapy [<a href="#rid49">49,51-57</a>]. The estimated incidence is &lt;1 percent with single-agent therapy and up to 2 percent with combination therapy (eg, <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> plus <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>). In a retrospective series of 19 patients with checkpoint inhibitor-related neuropathy, the most common phenotypes were cranial neuropathies with or without meningitis (37 percent) and non-length-dependent polyradiculoneuropathies with and without cranial nerve involvement (32 percent), including GBS-like syndromes [<a href="#rid49">49</a>]. Cases of small fiber/autonomic neuropathy, antineutrophil cytoplasmic antibody (ANCA)-associated mononeuritis multiplex, acute length-dependent sensorimotor axonal polyneuropathy, sensory neuronopathy, and neuralgic amyotrophy have also been described. Compared with cytotoxic chemotherapy-induced neuropathy, presentations are more likely to be acute/subacute, to be non-length dependent, and to involve additional organ systems [<a href="#rid49">49</a>]. Neuropathy onset occurred after a median of four cycles of immunotherapy.</p><p>Electrodiagnostic studies and CSF testing should be performed in most patients to characterize the neuropathy; detect coexisting meningitis, inflammatory myopathy, or neuromuscular junction disease; and rule out infectious and direct neoplastic involvement (eg, leptomeningeal metastases). Axonal pathophysiology appears to be more common than demyelinating pathophysiology based on nerve conduction studies (NCS). Approximately half of patients have a mild to moderate pleocytosis and/or elevated protein in CSF [<a href="#rid49">49</a>]. Brain and spine MRI with and without contrast may show gadolinium enhancement of cranial nerves or spinal nerve roots. Such findings are nonspecific but may lend further support to an inflammatory etiology in the context of other test results.</p><p>Treatment includes glucocorticoids in most cases and temporary or permanent withdrawal of checkpoint inhibitor therapy, depending on the severity of the toxicity  (<a class="graphic graphic_table graphicRef116846" href="/d/graphic/116846.html" rel="external">table 2</a>). Most patients improve with glucocorticoid therapy [<a href="#rid58">58</a>], although deaths have been reported in association with respiratory failure [<a href="#rid49">49,56,59</a>]. Intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) and <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> have been used in severe or relapsing cases [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H2400313842"><span class="h1">NEUROMUSCULAR JUNCTION</span></p><p class="headingAnchor" id="H3172674699"><span class="h2">Lambert-Eaton myasthenic syndrome</span><span class="headingEndMark"> — </span>The Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disorder of the neuromuscular junction caused by antibodies directed against voltage-gated calcium channels (VGCC). Approximately 50 percent of patients with LEMS have cancer, almost always small cell lung cancer (SCLC). The presence of antibodies against SOX1 in patients with LEMS predicts the presence of an SCLC [<a href="#rid60">60</a>]. As is often seen with paraneoplastic neurologic syndromes, the neurologic symptoms usually precede the detection of the neoplasm. Some patients have combined paraneoplastic cerebellar degeneration and LEMS. (See  <a class="medical medical_review" href="/d/html/15822.html" rel="external">"Paraneoplastic cerebellar degeneration"</a>.) </p><p>The clinical features, diagnosis, and treatment of LEMS are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/5174.html" rel="external">"Lambert-Eaton myasthenic syndrome: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5134.html" rel="external">"Lambert-Eaton myasthenic syndrome: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H1771583538"><span class="h2">Myasthenia gravis</span><span class="headingEndMark"> — </span>Myasthenia gravis is an autoimmune disorder of the neuromuscular junction caused in approximately 85 percent of patients by antibodies against the acetylcholine receptor (AChR) [<a href="#rid61">61</a>]. In approximately 10 percent of patients, myasthenia is a paraneoplastic manifestation of a thymic tumor, most commonly thymoma. Thymectomy is indicated in these patients and often results in an improvement in symptoms. Diagnosis and management of myasthenia with and without associated thymoma are reviewed separately. (See  <a class="medical medical_review" href="/d/html/5170.html" rel="external">"Clinical manifestations of myasthenia gravis"</a> and  <a class="medical medical_review" href="/d/html/5130.html" rel="external">"Diagnosis of myasthenia gravis"</a> and  <a class="medical medical_review" href="/d/html/5157.html" rel="external">"Overview of the treatment of myasthenia gravis"</a>.)</p><p>Aside from thymoma, myasthenia gravis rarely occurs in patients with other cancers (SCLC, thyroid and breast cancers, and Hodgkin lymphoma). In such cases, a paraneoplastic association is less clear. An exception may be rare cases of myasthenia gravis seen in association with follicular dendritic cell sarcoma [<a href="#rid62">62,63</a>]. (See  <a class="medical medical_review" href="/d/html/112363.html" rel="external">"Follicular dendritic cell sarcoma"</a>.)</p><p>New-onset myasthenia gravis or exacerbation of previously diagnosed myasthenia have been reported as an immune-related adverse event in cancer patients treated with immune checkpoint inhibitors [<a href="#rid64">64</a>]. Some patients may have concomitant immune-related myositis and/or myocarditis. (See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Neurologic'</a>.)</p><p class="headingAnchor" id="H3104518438"><span class="h1">MUSCLE FUNCTION</span></p><p class="headingAnchor" id="H2075849718"><span class="h2">Dermatomyositis and polymyositis</span><span class="headingEndMark"> — </span>Dermatomyositis and polymyositis are idiopathic inflammatory myopathies characterized by proximal skeletal muscle weakness and evidence of muscle inflammation. In adults, dermatomyositis often associates with malignancy. This is less clear for polymyositis, with cohort studies reporting conflicting results. </p><p>Approximately 10 to 15 percent of adults with dermatomyositis are diagnosed with a malignancy, usually within the first two to three years after diagnosis [<a href="#rid65">65</a>]. As a result of this, active tumor surveillance is recommended during this period. The risk of cancer also appears to be higher in women. Certain serum myositis antibodies appear to confer increased risk of cancer (eg, antibodies to nuclear matrix protein 2 [NXP-2] and transcription intermediary factor 1 gamma). The most common tumors are cancer of the breast, lung, ovary, and stomach, and non-Hodgkin lymphoma. (See  <a class="medical medical_review" href="/d/html/5162.html" rel="external">"Malignancy in dermatomyositis and polymyositis"</a>.)</p><p>The diagnosis and treatment of dermatomyositis and polymyositis are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/5159.html" rel="external">"Clinical manifestations of dermatomyositis and polymyositis in adults"</a> and  <a class="medical medical_review" href="/d/html/5160.html" rel="external">"Initial treatment of dermatomyositis and polymyositis in adults"</a>.)</p><p class="headingAnchor" id="H1440953462"><span class="h2">Acute necrotizing myopathy</span><span class="headingEndMark"> — </span>Immune-mediated necrotizing myopathy is a rare disorder characterized by symmetric, painful, predominantly proximal weakness leading to severe disability over one to three months [<a href="#rid66">66</a>]. The serum creatine kinase concentration is markedly elevated, and muscle biopsy shows minimal inflammation, patchy necrosis, and perimysial alkaline phosphatase staining. The etiology can be drug induced (eg, statins), idiopathic, associated with a connective tissue disorder, or paraneoplastic. (See  <a class="medical medical_review" href="/d/html/6833.html" rel="external">"Statin muscle-related adverse events", section on 'Neuromuscular disorders'</a>.)</p><p>In one series of 115 patients with necrotizing myopathy, 10 percent of patients had an associated malignancy diagnosed within three years before or after the myopathy [<a href="#rid67">67</a>]. An additional 5 percent of patients had a more remote cancer diagnosis. Most cancers were adenocarcinomas (eg, breast, gastric, hepatocellular, bladder, endometrial). Patients with antibodies to 3-hydroxy-3-methyglutaryl-coenzyme A (HMG-CoA) or without myositis-specific antibodies were more likely to have cancer than those with antibodies to signal recognition particle (SRP). Of note, HMG-CoA antibodies were seen in patients with and without prior statin exposure.</p><p>Glucocorticoids combined with other immunosuppressive therapies and tumor treatment (when appropriate) can result in neurologic improvement. Patients with cancer have worse outcomes [<a href="#rid68">68,69</a>]. </p><p class="headingAnchor" id="H3021884761"><span class="h2">Paraneoplastic neuromyotonia</span><span class="headingEndMark"> — </span>Neuromyotonia, also called peripheral nerve hyperexcitability or Isaacs syndrome, is characterized by muscle cramps and stiffness associated with spontaneous and continuous muscle fiber activity of peripheral nerve origin [<a href="#rid70">70</a>]. It is often associated with a sensorimotor polyneuropathy. Thymoma, small cell lung cancer (SCLC), and Hodgkin lymphoma are the most commonly associated neoplasms [<a href="#rid70">70,71</a>].</p><p>In some cases, neuromyotonia is associated with antibodies to contactin-associated protein-like 2 (Caspr2), and approximately 20 percent of these patients have thymoma [<a href="#rid72">72,73</a>]. Rarely, patients with predominant neuromyotonia may have antibodies to leucine-rich glioma inactivated 1 (LGI1), a protein related to potassium channels [<a href="#rid74">74</a>]. Many patients with neuromyotonia are antibody negative, but this does not rule out a paraneoplastic etiology [<a href="#rid75">75</a>]. (See  <a class="medical medical_review" href="/d/html/15759.html" rel="external">"Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis", section on 'Anti-LGI1 encephalitis'</a>.)</p><p>Symptoms include muscle cramps, muscle twitching (myokymia, fasciculations), stiffness, pseudomyotonia (delayed relaxation), carpopedal spasms, increased sweating, and sometimes motor weakness. The involved muscles are often hypertrophic. Intestinal pseudo-obstruction occurs rarely [<a href="#rid76">76</a>]. The serum creatine kinase concentration may be elevated.</p><p>Patients with neuromyotonia may develop symptoms of central nervous system (CNS) dysfunction, including confusion, memory loss, hallucinations, seizures, insomnia, and other sleep alterations, which are collectively referred to as "agrypnia excitata." The association of neuromyotonia and CNS symptoms is called Morvan syndrome and is usually accompanied by prominent autonomic dysfunction; it often occurs with antibodies against Caspr2, and 40 percent of these patients have an underlying thymoma [<a href="#rid77">77-79</a>].</p><p>The electromyogram (EMG) shows fibrillations, fasciculations, and spontaneous firing of single motor units as doublet, triplet, or multiplet discharges that have a high intraburst frequency and occur at irregular intervals [<a href="#rid80">80</a>]. These motor discharges persist during sleep, general anesthesia, and proximal nerve block, and they may disappear by blocking the neuromuscular junction.</p><p>The autoimmune basis of this disorder, whether paraneoplastic or otherwise acquired, is suggested by the response to immunotherapy and demonstration of antibodies in some patients  (<a class="graphic graphic_table graphicRef135170" href="/d/graphic/135170.html" rel="external">table 1</a>). The absence of antibodies does not rule out a paraneoplastic etiology, however, and patients with neuromyotonia should be screened for thymoma and other tumors [<a href="#rid70">70,81,82</a>].</p><p>Treatment with plasma exchange or intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) is usually of benefit; other potentially effective treatments include <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, and <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a> [<a href="#rid70">70,83</a>].</p><p class="headingAnchor" id="H1650710650"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117968.html" rel="external">"Society guideline links: Paraneoplastic neurologic disorders"</a>.)</p><p class="headingAnchor" id="H30092542"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spinal cord syndromes</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Myelopathy</strong> – Rapidly progressive myelopathy (spastic paresis, sensory loss, with or without bowel and bladder dysfunction) can occur as an isolated paraneoplastic syndrome or, more commonly, in association with involvement of other areas of the nervous system. Antibodies that may be detected include anti-Hu, anti-collapsin-responsive mediator protein 5 (CRMP5), and, less frequently, antiamphiphysin  (<a class="graphic graphic_table graphicRef135170" href="/d/graphic/135170.html" rel="external">table 1</a>). (See <a class="local">'Myelopathy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subacute motor neuronopathy</strong> – Paraneoplastic degeneration of the anterior horn cells causes subacute, progressive, painless, and often asymmetric lower motor neuron weakness. The disorder has been described primarily in association with lymphoma. (See <a class="local">'Subacute motor neuronopathy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stiff-person syndrome</strong> – Rare cases of stiff-person syndrome have a paraneoplastic etiology, often associated with antiamphiphysin antibodies. Breast cancer and small cell lung cancer (SCLC) are the most commonly associated neoplasms. (See <a class="local">'Stiff-person syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dorsal root ganglia syndromes</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subacute sensory neuronopathy</strong> – Sensory neuronopathy is a particularly disabling form of sensory loss presenting with loss of vibratory and joint position sense and sensory ataxia; other sensory modalities become impaired as well. Asymmetric radicular pain and dysesthesias can be the presenting symptoms. Most patients have SCLC and anti-Hu antibodies. (See <a class="local">'Subacute sensory neuronopathy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peripheral nerve syndromes</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute sensorimotor radiculoneuropathy</strong> – A syndrome identical to the Guillain-Barré syndrome (GBS) may occur as a paraneoplastic syndrome, usually in association with Hodgkin lymphoma. Treatment and prognosis is similar to that for GBS that is not associated with cancer. (See <a class="local">'Acute sensorimotor radiculoneuropathy'</a> above and  <a class="medical medical_review" href="/d/html/5172.html" rel="external">"Guillain-Barré syndrome in adults: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sensorimotor neuropathy</strong> – Paraneoplastic sensorimotor neuropathies range from mild, nondisabling forms associated with advanced cancer to more severe and disabling neuropathies associated with autoantibodies (eg, anti-CRMP5/CV2, antiamphiphysin) or a variety of plasma cell dyscrasias. (See <a class="local">'Chronic sensorimotor neuropathy'</a> above and <a class="local">'Neuropathies associated with lymphoproliferative disorders'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Autonomic neuropathy</strong> – Autonomic dysfunction can occur as an isolated paraneoplastic syndrome or in association with other neurologic syndromes. When seen along with paraneoplastic encephalomyelitis, it is often associated with SCLC and anti-Hu antibodies. When isolated, it may associate with ganglionic acetylcholine receptor (AChR) antibodies (autoimmune autonomic ganglionopathy), usually in the absence of an underlying cancer. (See <a class="local">'Autonomic neuropathy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vasculitic neuropathy</strong> – Paraneoplastic peripheral nerve vasculitis typically presents with painful, asymmetric sensorimotor deficits resembling a multifocal mononeuropathy. Biopsy demonstrates the vasculitis. (See <a class="local">'Vasculitic neuropathy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuromuscular junction syndromes</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lambert-Eaton myasthenic syndrome</strong> – Lambert-Eaton is an autoimmune disorder of the neuromuscular junction caused by antibodies against voltage-gated calcium channels. Approximately 50 percent of patients have cancer, almost always SCLC. (See  <a class="medical medical_review" href="/d/html/5174.html" rel="external">"Lambert-Eaton myasthenic syndrome: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5134.html" rel="external">"Lambert-Eaton myasthenic syndrome: Treatment and prognosis"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Muscle syndromes</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dermatomyositis </strong>– Dermatomyositis is the inflammatory myopathy most commonly associated with malignancy. Acute necrotizing myopathy is a rarer and more severe muscle disorder that can occur in association with cancer. (See  <a class="medical medical_review" href="/d/html/5162.html" rel="external">"Malignancy in dermatomyositis and polymyositis"</a> and <a class="local">'Acute necrotizing myopathy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neuromyotonia</strong> – Neuromyotonia (Isaacs syndrome) is characterized by muscle cramps and stiffness, muscle twitching (myokymias, fasciculations) during rest, delayed muscle relaxation, carpopedal spasms, increased sweating, local muscle hypertrophy, and sometimes motor weakness. Thymoma, SCLC, and Hodgkin lymphoma are the most commonly associated neoplasms. Some of these patients have antibodies against contactin-associated protein-like 2 (Caspr2). (See <a class="local">'Paraneoplastic neuromyotonia'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992; 71:59.</a></li><li><a class="nounderline abstract_t">Kleinig TJ, Thompson PD, Kneebone CS. Chorea, transverse myelitis, neuropathy and a distinctive MRI: paraneoplastic manifestations of probable small cell lung cancer. J Clin Neurosci 2009; 16:964.</a></li><li><a class="nounderline abstract_t">Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001; 49:146.</a></li><li><a class="nounderline abstract_t">Flanagan EP, McKeon A, Lennon VA, et al. Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues. Neurology 2011; 76:2089.</a></li><li><a class="nounderline abstract_t">Pittock SJ, Lennon VA. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol 2008; 65:629.</a></li><li><a class="nounderline abstract_t">Sepúlveda M, Sola-Valls N, Escudero D, et al. Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies. Mult Scler 2018; 24:1753.</a></li><li><a class="nounderline abstract_t">Urai Y, Matsumoto K, Shimamura M, et al. Paraneoplastic necrotizing myelopathy in a patient with advanced esophageal cancer: An autopsied case report. J Neurol Sci 2009; 280:113.</a></li><li class="breakAll">Posner JB. Neurologic Complications of Cancer, FA Davis, 1995.</li><li><a class="nounderline abstract_t">Zalewski NL, Flanagan EP. Autoimmune and Paraneoplastic Myelopathies. Semin Neurol 2018; 38:278.</a></li><li><a class="nounderline abstract_t">Schold SC, Cho ES, Somasundaram M, Posner JB. Subacute motor neuronopathy: a remote effect of lymphoma. Ann Neurol 1979; 5:271.</a></li><li><a class="nounderline abstract_t">Plante-Bordeneuve V, Baudrimont M, Gorin NC, Gherardi RK. Subacute sensory neuropathy associated with Hodgkin's disease. J Neurol Sci 1994; 121:155.</a></li><li><a class="nounderline abstract_t">Hughes RA, Britton T, Richards M. Effects of lymphoma on the peripheral nervous system. J R Soc Med 1994; 87:526.</a></li><li><a class="nounderline abstract_t">Noguchi M, Mori K, Yamazaki S, et al. Multifocal motor neuropathy caused by a B-cell lymphoma producing a monoclonal IgM autoantibody against peripheral nerve myelin glycolipids GM1 and GD1b. Br J Haematol 2003; 123:600.</a></li><li><a class="nounderline abstract_t">Flanagan EP, Sandroni P, Pittock SJ, et al. Paraneoplastic lower motor neuronopathy associated with Hodgkin lymphoma. Muscle Nerve 2012; 46:823.</a></li><li><a class="nounderline abstract_t">Helfgott SM. Stiff-man syndrome: from the bedside to the bench. Arthritis Rheum 1999; 42:1312.</a></li><li><a class="nounderline abstract_t">Shaw PJ. Stiff-man syndrome and its variants. Lancet 1999; 353:86.</a></li><li><a class="nounderline abstract_t">Casadevall T, Costa-Jussà F, Llufriu S, et al. [Pruritus as initial manifestation of a paraneoplastic stiff person syndrome associated to anti-amphiphysin antibodies]. Neurologia 2009; 24:215.</a></li><li><a class="nounderline abstract_t">Folli F, Solimena M, Cofiell R, et al. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 1993; 328:546.</a></li><li><a class="nounderline abstract_t">Grimaldi LM, Martino G, Braghi S, et al. Heterogeneity of autoantibodies in stiff-man syndrome. Ann Neurol 1993; 34:57.</a></li><li><a class="nounderline abstract_t">Murinson BB, Guarnaccia JB. Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease. Neurology 2008; 71:1955.</a></li><li><a class="nounderline abstract_t">De Camilli P, Thomas A, Cofiell R, et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. J Exp Med 1993; 178:2219.</a></li><li><a class="nounderline abstract_t">Solimena M, Folli F, Aparisi R, et al. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 1990; 322:1555.</a></li><li><a class="nounderline abstract_t">McKeon A, Martinez-Hernandez E, Lancaster E, et al. Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol 2013; 70:44.</a></li><li><a class="nounderline abstract_t">Carvajal-González A, Leite MI, Waters P, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain 2014; 137:2178.</a></li><li><a class="nounderline abstract_t">Martinez-Hernandez E, Ariño H, McKeon A, et al. Clinical and Immunologic Investigations in Patients With Stiff-Person Spectrum Disorder. JAMA Neurol 2016; 73:714.</a></li><li><a class="nounderline abstract_t">Chalk CH, Windebank AJ, Kimmel DW, McManis PG. The distinctive clinical features of paraneoplastic sensory neuronopathy. Can J Neurol Sci 1992; 19:346.</a></li><li><a class="nounderline abstract_t">DENNY-BROWN D. Primary sensory neuropathy with muscular changes associated with carcinoma. J Neurol Neurosurg Psychiatry 1948; 11:73.</a></li><li><a class="nounderline abstract_t">Oki Y, Koike H, Iijima M, et al. Ataxic vs painful form of paraneoplastic neuropathy. Neurology 2007; 69:564.</a></li><li><a class="nounderline abstract_t">Camdessanché JP, Jousserand G, Ferraud K, et al. The pattern and diagnostic criteria of sensory neuronopathy: a case-control study. Brain 2009; 132:1723.</a></li><li><a class="nounderline abstract_t">Antoine JC, Honnorat J, Camdessanché JP, et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol 2001; 49:214.</a></li><li><a class="nounderline abstract_t">Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011; 18:19.</a></li><li><a class="nounderline abstract_t">Gwathmey KG. Sensory neuronopathies. Muscle Nerve 2016; 53:8.</a></li><li><a class="nounderline abstract_t">Amato AA, Ropper AH. Sensory Ganglionopathy. N Engl J Med 2020; 383:1657.</a></li><li><a class="nounderline abstract_t">Uchuya M, Graus F, Vega F, et al. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry 1996; 60:388.</a></li><li><a class="nounderline abstract_t">Giometto B, Vitaliani R, Lindeck-Pozza E, et al. Treatment for paraneoplastic neuropathies. Cochrane Database Syst Rev 2012; 12:CD007625.</a></li><li><a class="nounderline abstract_t">Keime-Guibert F, Graus F, Fleury A, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000; 68:479.</a></li><li><a class="nounderline abstract_t">Oh SJ, Dropcho EJ, Claussen GC. Anti-Hu-associated paraneoplastic sensory neuropathy responding to early aggressive immunotherapy: report of two cases and review of literature. Muscle Nerve 1997; 20:1576.</a></li><li><a class="nounderline abstract_t">Vigliani MC, Magistrello M, Polo P, et al. Risk of cancer in patients with Guillain-Barré syndrome (GBS). A population-based study. J Neurol 2004; 251:321.</a></li><li><a class="nounderline abstract_t">Veilleux M, Bernier JP, Lamarche JB. Paraneoplastic encephalomyelitis and subacute dysautonomia due to an occult atypical carcinoid tumour of the lung. Can J Neurol Sci 1990; 17:324.</a></li><li><a class="nounderline abstract_t">Lennon VA, Sas DF, Busk MF, et al. Enteric neuronal autoantibodies in pseudoobstruction with small-cell lung carcinoma. Gastroenterology 1991; 100:137.</a></li><li><a class="nounderline abstract_t">Horta E, McKeon A, Lennon VA, Benarroch EE. Reversible paraneoplastic tonic pupil with PCA-Tr IgG and Hodgkin lymphoma. Neurology 2012; 78:1620.</a></li><li><a class="nounderline abstract_t">McKeon A, Lennon VA, Lachance DH, et al. Ganglionic acetylcholine receptor autoantibody: oncological, neurological, and serological accompaniments. Arch Neurol 2009; 66:735.</a></li><li><a class="nounderline abstract_t">Li Y, Jammoul A, Mente K, et al. Clinical experience of seropositive ganglionic acetylcholine receptor antibody in a tertiary neurology referral center. Muscle Nerve 2015; 52:386.</a></li><li><a class="nounderline abstract_t">Gibbons CH, Vernino SA, Freeman R. Combined immunomodulatory therapy in autoimmune autonomic ganglionopathy. Arch Neurol 2008; 65:213.</a></li><li><a class="nounderline abstract_t">Kannan MA, Challa S, Kandadai RM, et al. Series of paraneoplastic vasculitic neuropathy: a rare, potentially treatable neuropathy. Neurol India 2015; 63:30.</a></li><li><a class="nounderline abstract_t">Oh SJ. Paraneoplastic vasculitis of the peripheral nervous system. Neurol Clin 1997; 15:849.</a></li><li><a class="nounderline abstract_t">Matsumuro K, Izumo S, Umehara F, et al. Paraneoplastic vasculitic neuropathy: immunohistochemical studies on a biopsied nerve and post-mortem examination. J Intern Med 1994; 236:225.</a></li><li><a class="nounderline abstract_t">Vincent D, Gombert B, Vital A, Vital C. A case of mononeuropathy multiplex with type II cryoglobulinemia, necrotizing vasculitis and low grade B cell lymphoma. Clin Neuropathol 2007; 26:28.</a></li><li><a class="nounderline abstract_t">Dubey D, David WS, Amato AA, et al. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology 2019; 93:e1093.</a></li><li><a class="nounderline abstract_t">Graus F, Dalmau J. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 2019; 16:535.</a></li><li><a class="nounderline abstract_t">Supakornnumporn S, Katirji B. Guillain-Barré Syndrome Triggered by Immune Checkpoint Inhibitors: A Case Report and Literature Review. J Clin Neuromuscul Dis 2017; 19:80.</a></li><li><a class="nounderline abstract_t">Gu Y, Menzies AM, Long GV, et al. Immune mediated neuropathy following checkpoint immunotherapy. J Clin Neurosci 2017; 45:14.</a></li><li><a class="nounderline abstract_t">Diamantopoulos PT, Tsatsou K, Benopoulou O, et al. Inflammatory Myopathy and Axonal Neuropathy in a Patient With Melanoma Following Pembrolizumab Treatment. J Immunother 2017; 40:221.</a></li><li><a class="nounderline abstract_t">Sepúlveda M, Martinez-Hernandez E, Gaba L, et al. Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma. Muscle Nerve 2017; 56:E162.</a></li><li><a class="nounderline abstract_t">Kao JC, Liao B, Markovic SN, et al. Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies. JAMA Neurol 2017; 74:1216.</a></li><li><a class="nounderline abstract_t">Mancone S, Lycan T, Ahmed T, et al. Severe neurologic complications of immune checkpoint inhibitors: a single-center review. J Neurol 2018; 265:1636.</a></li><li><a class="nounderline abstract_t">Damato V, Berretta A, Ramanathan S, et al. Association Between a Distinctive Autoantibody-Associated Brainstem Sensory Syndrome and Immune Checkpoint Inhibitors. JAMA Neurol 2022; 79:949.</a></li><li><a class="nounderline abstract_t">Larkin J, Chmielowski B, Lao CD, et al. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. Oncologist 2017; 22:709.</a></li><li><a class="nounderline abstract_t">Reynolds KL, Guidon AC. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature. Oncologist 2019; 24:435.</a></li><li><a class="nounderline abstract_t">Sabater L, Titulaer M, Saiz A, et al. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 2008; 70:924.</a></li><li><a class="nounderline abstract_t">Gilhus NE. Myasthenia Gravis. N Engl J Med 2016; 375:2570.</a></li><li><a class="nounderline abstract_t">Hsu C, Vega F, Grimes LM, Hunt KK. Follicular dendritic cell sarcoma and associated myasthenia gravis: true, true, related? J Clin Oncol 2011; 29:e369.</a></li><li><a class="nounderline abstract_t">Hartert M, Ströbel P, Dahm M, et al. A follicular dendritic cell sarcoma of the mediastinum with immature T cells and association with myasthenia gravis. Am J Surg Pathol 2010; 34:742.</a></li><li><a class="nounderline abstract_t">Puwanant A, Isfort M, Lacomis D, Živković SA. Clinical spectrum of neuromuscular complications after immune checkpoint inhibition. Neuromuscul Disord 2019; 29:127.</a></li><li><a class="nounderline abstract_t">Yang Z, Lin F, Qin B, et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol 2015; 42:282.</a></li><li><a class="nounderline abstract_t">Levin MI, Mozaffar T, Al-Lozi MT, Pestronk A. Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology 1998; 50:764.</a></li><li><a class="nounderline abstract_t">Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain 2016; 139:2131.</a></li><li><a class="nounderline abstract_t">Sampson JB, Smith SM, Smith AG, et al. Paraneoplastic myopathy: response to intravenous immunoglobulin. Neuromuscul Disord 2007; 17:404.</a></li><li><a class="nounderline abstract_t">Bronner IM, Hoogendijk JE, Wintzen AR, et al. Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy. J Neurol 2003; 250:480.</a></li><li><a class="nounderline abstract_t">Newsom-Davis J, Mills KR. Immunological associations of acquired neuromyotonia (Isaacs' syndrome). Report of five cases and literature review. Brain 1993; 116 ( Pt 2):453.</a></li><li><a class="nounderline abstract_t">Walsh JC. Neuromyotonia: an unusual presentation of intrathoracic malignancy. J Neurol Neurosurg Psychiatry 1976; 39:1086.</a></li><li><a class="nounderline abstract_t">Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010; 9:776.</a></li><li><a class="nounderline abstract_t">van Sonderen A, Ariño H, Petit-Pedrol M, et al. The clinical spectrum of Caspr2 antibody-associated disease. Neurology 2016; 87:521.</a></li><li><a class="nounderline abstract_t">Fleisher J, Richie M, Price R, et al. Acquired neuromyotonia heralding recurrent thymoma in myasthenia gravis. JAMA Neurol 2013; 70:1311.</a></li><li><a class="nounderline abstract_t">Rubio-Agusti I, Perez-Miralles F, Sevilla T, et al. Peripheral nerve hyperexcitability: a clinical and immunologic study of 38 patients. Neurology 2011; 76:172.</a></li><li><a class="nounderline abstract_t">Viallard JF, Vincent A, Moreau JF, et al. Thymoma-associated neuromyotonia with antibodies against voltage-gated potassium channels presenting as chronic intestinal pseudo-obstruction. Eur Neurol 2005; 53:60.</a></li><li><a class="nounderline abstract_t">Lancaster E, Huijbers MG, Bar V, et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 2011; 69:303.</a></li><li><a class="nounderline abstract_t">Irani SR, Pettingill P, Kleopa KA, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol 2012; 72:241.</a></li><li><a class="nounderline abstract_t">van Sonderen A, Petit-Pedrol M, Dalmau J, Titulaer MJ. The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis. Nat Rev Neurol 2017; 13:290.</a></li><li><a class="nounderline abstract_t">Hart IK, Maddison P, Newsom-Davis J, et al. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain 2002; 125:1887.</a></li><li><a class="nounderline abstract_t">Vincent A, Jacobson L, Plested P, et al. Antibodies affecting ion channel function in acquired neuromyotonia, in seropositive and seronegative myasthenia gravis, and in antibody-mediated arthrogryposis multiplex congenita. Ann N Y Acad Sci 1998; 841:482.</a></li><li><a class="nounderline abstract_t">Newsom-Davis J, Buckley C, Clover L, et al. Autoimmune disorders of neuronal potassium channels. Ann N Y Acad Sci 2003; 998:202.</a></li><li><a class="nounderline abstract_t">Issa SS, Herskovitz S, Lipton RB. Acquired neuromyotonia as a paraneoplastic manifestation of ovarian cancer. Neurology 2011; 76:100.</a></li></ol></div><div id="topicVersionRevision">Topic 5190 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1312211" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19329321" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Chorea, transverse myelitis, neuropathy and a distinctive MRI: paraneoplastic manifestations of probable small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11220734" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21670438" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18474738" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Aquaporin-4 autoantibodies in a paraneoplastic context.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28920766" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19272613" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Paraneoplastic necrotizing myelopathy in a patient with advanced esophageal cancer: An autopsied case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19272613" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Paraneoplastic necrotizing myelopathy in a patient with advanced esophageal cancer: An autopsied case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30011409" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Autoimmune and Paraneoplastic Myelopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/443760" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Subacute motor neuronopathy: a remote effect of lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8158207" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Subacute sensory neuropathy associated with Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7932460" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effects of lymphoma on the peripheral nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14616962" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Multifocal motor neuropathy caused by a B-cell lymphoma producing a monoclonal IgM autoantibody against peripheral nerve myelin glycolipids GM1 and GD1b.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23055320" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Paraneoplastic lower motor neuronopathy associated with Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10403257" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Stiff-man syndrome: from the bedside to the bench.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10023890" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Stiff-man syndrome and its variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19418303" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : [Pruritus as initial manifestation of a paraneoplastic stiff person syndrome associated to anti-amphiphysin antibodies].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8381208" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8517681" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Heterogeneity of autoantibodies in stiff-man syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18971449" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Stiff-person syndrome with amphiphysin antibodies: distinctive features of a rare disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8245793" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2135382" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23090334" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24951641" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27065452" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clinical and Immunologic Investigations in Patients With Stiff-Person Spectrum Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1393844" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The distinctive clinical features of paraneoplastic sensory neuronopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18861108" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Primary sensory neuropathy with muscular changes associated with carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17679675" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Ataxic vs painful form of paraneoplastic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19506068" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The pattern and diagnostic criteria of sensory neuronopathy: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11220741" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20880069" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26467754" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Sensory neuronopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33085862" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Sensory Ganglionopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8774401" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23235647" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Treatment for paraneoplastic neuropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10727484" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9390671" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Anti-Hu-associated paraneoplastic sensory neuropathy responding to early aggressive immunotherapy: report of two cases and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15015013" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Risk of cancer in patients with Guillain-Barrésyndrome (GBS). A population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2207890" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Paraneoplastic encephalomyelitis and subacute dysautonomia due to an occult atypical carcinoid tumour of the lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1845756" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Enteric neuronal autoantibodies in pseudoobstruction with small-cell lung carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22551727" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Reversible paraneoplastic tonic pupil with PCA-Tr IgG and Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19506133" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Ganglionic acetylcholine receptor autoantibody: oncological, neurological, and serological accompaniments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25557122" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clinical experience of seropositive ganglionic acetylcholine receptor antibody in a tertiary neurology referral center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18268189" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Combined immunomodulatory therapy in autoimmune autonomic ganglionopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25751466" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Series of paraneoplastic vasculitic neuropathy: a rare, potentially treatable neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9367968" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Paraneoplastic vasculitis of the peripheral nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8046323" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Paraneoplastic vasculitic neuropathy: immunohistochemical studies on a biopsied nerve and post-mortem examination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17290934" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A case of mononeuropathy multiplex with type II cryoglobulinemia, necrotizing vasculitis and low grade B cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31405908" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30867573" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29189553" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Guillain-BarréSyndrome Triggered by Immune Checkpoint Inhibitors: A Case Report and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28765062" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Immune mediated neuropathy following checkpoint immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28498142" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Inflammatory Myopathy and Axonal Neuropathy in a Patient With Melanoma Following Pembrolizumab Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28439919" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28873125" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29761297" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Severe neurologic complications of immune checkpoint inhibitors: a single-center review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35816342" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Association Between a Distinctive Autoantibody-Associated Brainstem Sensory Syndrome and Immune Checkpoint Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28495807" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30482825" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18032743" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28029925" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Myasthenia Gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21321294" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Follicular dendritic cell sarcoma and associated myasthenia gravis: true, true, related?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20305533" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A follicular dendritic cell sarcoma of the mediastinum with immature T cells and association with myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30638612" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Clinical spectrum of neuromuscular complications after immune checkpoint inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25448790" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9521271" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Paraneoplastic necrotizing myopathy: clinical and pathological features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27086869" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17336069" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Paraneoplastic myopathy: response to intravenous immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12700915" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8461975" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Immunological associations of acquired neuromyotonia (Isaacs' syndrome). Report of five cases and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1011019" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Neuromyotonia: an unusual presentation of intrathoracic malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20580615" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27371488" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The clinical spectrum of Caspr2 antibody-associated disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23978943" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Acquired neuromyotonia heralding recurrent thymoma in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21220721" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Peripheral nerve hyperexcitability: a clinical and immunologic study of 38 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15753614" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Thymoma-associated neuromyotonia with antibodies against voltage-gated potassium channels presenting as chronic intestinal pseudo-obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21387375" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22473710" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Morvan syndrome: clinical and serological observations in 29 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28418022" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12135978" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Phenotypic variants of autoimmune peripheral nerve hyperexcitability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9668280" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Antibodies affecting ion channel function in acquired neuromyotonia, in seropositive and seronegative myasthenia gravis, and in antibody-mediated arthrogryposis multiplex congenita.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14592877" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Autoimmune disorders of neuronal potassium channels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21205699" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Acquired neuromyotonia as a paraneoplastic manifestation of ovarian cancer.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
